PBV Stock Chart & Stats
€47.60
-€0.50(-0.70%)
At close: 4:00 PM EST
€47.60
-€0.50(-0.70%)
Day’s Range― - ―
52-Week Range€38.00 - €67.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.03B
Enterprise Value€3.17B
Total Cash (Recent Filing)€63.87M
Total Debt (Recent Filing)€1.05B
Price to Earnings (P/E)12.8
Beta0.21
Next Earnings
Jul 30, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.94
Shares Outstanding47,372,166
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€62.99Price Target Upside32.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)3.9
Revenue Forecast (FY)€1.02B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent, high free cash flow (~$230M–$260M historically) provides durable internal funding for M&A, buybacks, and debt paydown. Strong FCF conversion supports financial flexibility and reduces reliance on external financing, sustaining strategic options over the next 2–6 months.
Improving Balance Sheet / DeleveragingMaterial reductions in leverage and equity growth strengthen solvency and covenant headroom, enabling integration of acquisitions and capital returns. The step-change deleveraging increases resilience to shocks, though the drivers of the 2026 drop should be monitored for sustainability.
Margin Resilience And Low CapexStable mid-50s gross margins and low capital intensity underpin persistent high operating cash conversion and profitability. Low ongoing capex needs allow the company to sustain brand investment, marketing, and shareholder returns without eroding operating margins over the medium term.
Bears Say
Top-line WeaknessRecurrent flat-to-declining revenue trends limit the firm's ability to grow operating profit organically. With muted organic growth and a 2026 decline, sustaining margins and FCF growth will depend more on M&A and pricing, increasing execution dependency over the next several quarters.
Operational / Supply RiskProduction shutdowns and extended ramp timelines create persistent execution risk that can depress near-term sales and disturb retailer relationships. Repeated supply issues raise the chance of ongoing volatility in shipment timing and inventory, pressuring revenue for months while capacity normalizes.
Higher Near-term Leverage From AcquisitionsLarge, debt-funded deals increase secured borrowing and covenant reliance, raising leverage and refinancing risk in the near term. Even if accretive long term, the heavier debt load heightens sensitivity to integration execution and cash flow variability over the next 2–6 months.
PBV FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was €38.00 and its highest was €67.00 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is €2.03B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on May 13, 2026. The company reported €1.078 earnings per share for the quarter, missing the consensus estimate of €1.219 by -€0.14.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare does not currently pay dividends.
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.77.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,372,166 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of €1.078 in its last earnings report, missing expectations of €1.219. Following the earnings report the stock price went up 1.905%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in DE:PBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€62.99 (32.34% Upside)
€62.99 (32.34% Upside)
Blogger Sentiment
Neutral
DE:PBV Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €197.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.42%
12-Months-Change
Fundamentals
Return on Equity
10.29%
Trailing 12-Months
Asset Growth
2.66%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBV Company Deck
PBV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.View all DE:PBV earnings summariesPBV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€62.99
▲(32.34% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Options Prices
Currently, No data available
---










